Why are UK private ADHD clinics criticized?

Safety and oversight concerns in private ADHD care

Doctors and child-health advocates have raised alarms about a rise in private clinics prescribing stimulant medications to children without adequate, in-person assessments. Reports point to some providers relying on remote consultations or limited documentation before initiating powerful stimulants, creating risks for young patients.

Key concerns include:

• Incomplete diagnostic evaluation: ADHD shares symptoms with other conditions, and specialists warn that a thorough history, developmental assessment and, when needed, school reports or psychological testing are essential before drug treatment.
• Insufficient monitoring: Stimulant medications require baseline cardiovascular checks and ongoing follow-up for growth, sleep, mood and potential side effects.
• Potential for inappropriate prescribing: Without robust assessment, children may receive medication they do not need, or clinicians may miss co-existing conditions that change treatment choices.

Regulatory gaps are central to the critique. Private services can move quickly and may escape the oversight mechanisms applied to NHS services, producing inconsistent standards of care. Clinicians advising parents recommend seeking comprehensive assessments from accredited child-and-adolescent mental health services or paediatric specialists, asking for written diagnostic reports and treatment plans, and ensuring there is a clear schedule for monitoring.

Why this matters: stimulant treatments can be effective but carry risks if misapplied. Accurate diagnosis and structured follow-up protect children’s health and development. Strengthening regulation, improving transparency of private clinics’ assessment protocols, and helping families access multidisciplinary evaluation are immediate steps to reduce harm and restore trust in how childhood ADHD is diagnosed and treated.